Does the media prefer AKTS or CAMP?

In the previous week, Aktis Oncology had 1 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for CAMP4 Therapeutics. Aktis Oncology's average media sentiment score of 0.87 beat CAMP4 Therapeutics' score of 0.64 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KURA or CAMP?

In the previous week, Kura Oncology had 9 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 12 mentions for Kura Oncology and 3 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 0.64 beat Kura Oncology's score of 0.55 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ANL or CAMP?

Adlai Nortye has higher revenue and earnings than CAMP4 Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 151.47 -$35.53M N/A N/A CAMP4 Therapeutics $3.50M 61.50 -$80.40M -$2.32 N/A

Does the media refer more to ANL or CAMP?

In the previous week, Adlai Nortye had 2 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 5 mentions for Adlai Nortye and 3 mentions for CAMP4 Therapeutics. Adlai Nortye's average media sentiment score of 0.78 beat CAMP4 Therapeutics' score of 0.64 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLTX or CAMP?

In the previous week, CAMP4 Therapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 3 mentions for CAMP4 Therapeutics and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.10 beat CAMP4 Therapeutics' score of 0.64 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRVS or CAMP?

In the previous week, CAMP4 Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for CAMP4 Therapeutics and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.79 beat CAMP4 Therapeutics' score of 0.64 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CAMP4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CAMP4 Therapeutics (CAMP) Competitors

$3.43 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 -0.01 (-0.29%)

As of 04:10 PM Eastern

Compare

CAMP vs. AKTS, KURA, ANL, MLTX, and CRVS

Should you buy CAMP4 Therapeutics stock or one of its competitors? CAMP4 Therapeutics's main competitors and comparable companies include Aktis Oncology (AKTS), Kura Oncology (KURA), Adlai Nortye (ANL), MoonLake Immunotherapeutics (MLTX), and Corvus Pharmaceuticals (CRVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CAMP4 Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Aktis Oncology had 1 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for CAMP4 Therapeutics. Aktis Oncology's average media sentiment score of 0.87 beat CAMP4 Therapeutics' score of 0.64 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.8% of Aktis Oncology shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aktis Oncology has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Aktis Oncology's return on equity of 0.00% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Aktis Oncology currently has a consensus price target of $35.63, indicating a potential upside of 114.09%. CAMP4 Therapeutics has a consensus price target of $10.86, indicating a potential upside of 216.53%. Given CAMP4 Therapeutics' higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aktis Oncology has higher revenue and earnings than CAMP4 Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	137.60	-$63.73M	-$0.82	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

Summary

Aktis Oncology beats CAMP4 Therapeutics on 13 of the 15 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

CAMP4 Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.96	-$278.67M	-$3.37	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

Kura Oncology has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Kura Oncology has a net margin of -384.30% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Kura Oncology's return on equity of -207.18% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

In the previous week, Kura Oncology had 9 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 12 mentions for Kura Oncology and 3 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 0.64 beat Kura Oncology's score of 0.55 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology presently has a consensus target price of $25.69, indicating a potential upside of 161.32%. CAMP4 Therapeutics has a consensus target price of $10.86, indicating a potential upside of 216.53%. Given CAMP4 Therapeutics' higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Kura Oncology beats CAMP4 Therapeutics on 8 of the 13 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

35.2% of Adlai Nortye shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adlai Nortye has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Adlai Nortye's return on equity of 0.00% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Adlai Nortye has higher revenue and earnings than CAMP4 Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	151.47	-$35.53M	N/A	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

Adlai Nortye currently has a consensus target price of $29.50, suggesting a potential upside of 150.85%. CAMP4 Therapeutics has a consensus target price of $10.86, suggesting a potential upside of 216.53%. Given CAMP4 Therapeutics' higher possible upside, analysts clearly believe CAMP4 Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Adlai Nortye has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

In the previous week, Adlai Nortye had 2 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 5 mentions for Adlai Nortye and 3 mentions for CAMP4 Therapeutics. Adlai Nortye's average media sentiment score of 0.78 beat CAMP4 Therapeutics' score of 0.64 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adlai Nortye beats CAMP4 Therapeutics on 12 of the 15 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

MoonLake Immunotherapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. MoonLake Immunotherapeutics' return on equity of -82.53% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

CAMP4 Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

In the previous week, CAMP4 Therapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 3 mentions for CAMP4 Therapeutics and 2 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.10 beat CAMP4 Therapeutics' score of 0.64 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics presently has a consensus price target of $28.50, indicating a potential upside of 173.78%. CAMP4 Therapeutics has a consensus price target of $10.86, indicating a potential upside of 216.53%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CAMP4 Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.43
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

MoonLake Immunotherapeutics and CAMP4 Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 254.23%. CAMP4 Therapeutics has a consensus target price of $10.86, suggesting a potential upside of 216.53%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Corvus Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Corvus Pharmaceuticals' return on equity of -36.15% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

In the previous week, CAMP4 Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for CAMP4 Therapeutics and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.79 beat CAMP4 Therapeutics' score of 0.64 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CAMP4 Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Corvus Pharmaceuticals has higher earnings, but lower revenue than CAMP4 Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

Summary

Corvus Pharmaceuticals beats CAMP4 Therapeutics on 11 of the 15 factors compared between the two stocks.

Get CAMP4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAMP vs. The Competition

Export

Metric	CAMP4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$215.23M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-1.48	12.49	275.28	25.28
Price / Sales	61.50	1,151.22	562.38	78.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	3.36	16.55	10.52	5.92
Net Income	-$80.40M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-10.68%	-6.66%	-4.32%	-4.41%
1 Month Performance	-19.29%	-14.41%	-8.66%	-7.30%
1 Year Performance	-0.12%	5.91%	1.94%	-5.04%

CAMP4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAMP CAMP4 Therapeutics	3.4604 of 5 stars	$3.43 flat	$10.86 +216.5%	-4.5%	$215.23M	$3.50M	N/A	644	News Coverage Gap Down
AKTS Aktis Oncology	2.4018 of 5 stars	$17.93 +0.4%	$35.63 +98.7%	N/A	$963.47M	$6.50M	N/A	79
KURA Kura Oncology	3.5589 of 5 stars	$10.60 +0.6%	$25.69 +142.4%	-1.0%	$941.64M	$67.48M	N/A	260	Analyst Forecast
ANL Adlai Nortye	2.4042 of 5 stars	$14.55 +0.6%	$29.50 +102.8%	+619.3%	$936.70M	$5M	N/A	109	Analyst Forecast
MLTX MoonLake Immunotherapeutics	2.8949 of 5 stars	$10.84 -1.0%	$28.50 +162.8%	-2.3%	$919.84M	N/A	N/A	130	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAMP) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. AKTS, KURA, ANL, MLTX, and CRVS

How does CAMP4 Therapeutics compare to Aktis Oncology?

Summary

How does CAMP4 Therapeutics compare to Kura Oncology?

Summary

How does CAMP4 Therapeutics compare to Adlai Nortye?

Summary

How does CAMP4 Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does CAMP4 Therapeutics compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. AKTS, KURA, ANL, MLTX, and CRVS

How does CAMP4 Therapeutics compare to Aktis Oncology?

Does the media prefer AKTS or CAMP?

Do institutionals & insiders believe in AKTS or CAMP?

Is AKTS or CAMP more profitable?

Do analysts recommend AKTS or CAMP?

Which has stronger earnings and valuation, AKTS or CAMP?

Summary

How does CAMP4 Therapeutics compare to Kura Oncology?

Which has preferable earnings and valuation, KURA or CAMP?

Which has more volatility & risk, KURA or CAMP?

Is KURA or CAMP more profitable?

Does the media refer more to KURA or CAMP?

Do analysts rate KURA or CAMP?

Summary

How does CAMP4 Therapeutics compare to Adlai Nortye?

Do institutionals & insiders have more ownership in ANL or CAMP?

Is ANL or CAMP more profitable?

Which has better earnings & valuation, ANL or CAMP?

Do analysts recommend ANL or CAMP?

Which has more volatility and risk, ANL or CAMP?

Does the media refer more to ANL or CAMP?

Summary

How does CAMP4 Therapeutics compare to MoonLake Immunotherapeutics?

Which has more risk & volatility, MLTX or CAMP?

Do insiders and institutionals have more ownership in MLTX or CAMP?

Is MLTX or CAMP more profitable?

Which has higher valuation and earnings, MLTX or CAMP?

Does the media favor MLTX or CAMP?

Do analysts rate MLTX or CAMP?

Summary

How does CAMP4 Therapeutics compare to Corvus Pharmaceuticals?

Do analysts rate CRVS or CAMP?

Which has more volatility and risk, CRVS or CAMP?

Is CRVS or CAMP more profitable?

Does the media prefer CRVS or CAMP?

Do insiders & institutionals believe in CRVS or CAMP?

Which has higher valuation and earnings, CRVS or CAMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools